Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > Pembrolizumab plus lenvatinib performs well in MPM

Pembrolizumab plus lenvatinib performs well in MPM

Presented By
Dr Li-Anne Douma, Netherlands Cancer Institute - Antoni van Leeuwenhoek, the Netherlands
Conference
WCLC 2022
Trial
Phase 2, PEMMELA
Doi
https://doi.org/10.55788/942c2d29
The combination of pembrolizumab plus lenvatinib displayed promising clinical activity in the second-line treatment of patients with malignant pleural mesothelioma (MPM) in the phase 2 PEMMELA study. According to the authors, the combination therapy showed remarkable but manageable toxicity [1]. “There is no standard second-line treatment for patients with MPM,” explained Dr Li-Anne Douma (Netherlands Cancer Institute - Antoni van Leeuwenhoek, the Netherlands). The current phase 2 study (NCT04287829) evaluated the safety and efficacy of pembrolizumab and lenvatinib in 38 patients with recurrent MPM. The included patients received up to 35 cycles of the combination therapy and objective response rate (ORR) was the primary endpoint of the trial. The ORR was 58%, exceeding the expectations of the investigators. All of the 22 responses were partial, and all othe...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on